Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Gilead Sciences, Inc.'s quarterly P/E stands at 17.6x, up 8.4% year-over-year. EV/EBITDA has expanded 55.1% YoY to 16.5x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 391.97 | 17.64 | 11.42 | 17.77 | 26.94 | 16.26 | 20.96 | 13.30 | — | 17.77 | 10.83 | 23.21 | 25.93 |
| — | +8.4% | -45.5% | +33.6% | — | -8.5% | +93.5% | -42.7% | — | +7.6% | -0.3% | +36.7% | -98.3% | |
| P/S Ratio | 6.45 | 4.85 | 4.48 | 4.91 | 5.29 | 3.84 | 3.48 | 3.09 | 3.42 | 3.58 | 3.34 | 3.67 | 4.12 |
| — | +26.3% | +28.6% | +59.2% | +54.9% | +7.4% | +4.3% | -16.0% | -17.1% | -2.6% | +21.0% | +18.1% | +44.7% | |
| P/B Ratio | 9.71 | 6.80 | 6.49 | 7.10 | 7.39 | 6.04 | 5.72 | 4.72 | 5.23 | 4.47 | 4.24 | 4.60 | 5.00 |
| — | +12.5% | +13.5% | +50.6% | +41.3% | +35.1% | +35.0% | +2.6% | +4.7% | -12.6% | +14.6% | +19.3% | +32.6% | |
| P/FCF | 18.01 | 11.56 | 8.79 | 48.31 | 21.34 | 10.28 | 6.31 | 17.96 | 10.80 | 13.02 | 14.42 | 11.02 | 16.00 |
| — | +12.4% | +39.3% | +169.1% | +97.5% | -21.0% | -56.3% | +62.9% | -32.5% | +14.5% | +100.7% | -6.1% | +35.9% | |
| EV / EBITDA | 45.68 | 16.47 | 9.77 | 12.55 | 13.48 | 10.62 | 19.54 | 7.97 | — | 13.19 | 8.58 | 12.41 | 13.32 |
| — | +55.1% | -50.0% | +57.5% | — | -19.5% | +127.8% | -35.8% | — | +14.9% | +17.3% | +27.6% | -60.3% | |
| EV / EBIT | 121.73 | 16.47 | 10.06 | 14.81 | 20.70 | 13.83 | 25.83 | 11.62 | — | 15.92 | 11.13 | 16.02 | 20.41 |
| — | +19.1% | -61.1% | +27.5% | — | -13.2% | +132.1% | -27.5% | — | +12.0% | +20.4% | +12.5% | -92.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Gilead Sciences, Inc.'s operating margin was 37.4% in Q4 2025, down 5.4 pp QoQ and up 5.0 pp YoY. Gross margin expanded 9.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 86.8% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% | 77.8% | 76.8% | 70.6% | 77.8% | 78.1% | 77.9% |
| — | +9.8% | +0.8% | +1.3% | +0.1% | +12.0% | +1.7% | -0.5% | -1.5% | -12.9% | -3.0% | +1.5% | -0.6% | |
| Operating Margin | 5.8% | 37.4% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% | 38.0% | -64.6% | 22.7% | 37.2% | 25.2% | 26.8% |
| — | +15.5% | +263.9% | -8.1% | +151.9% | +43.0% | -68.4% | +50.7% | -340.8% | -26.1% | -7.6% | -22.2% | +797.9% | |
| Net Margin | 1.7% | 27.5% | 39.3% | 27.7% | 19.7% | 23.6% | 16.6% | 23.2% | -62.4% | 20.1% | 30.9% | 15.8% | 15.9% |
| — | +16.9% | +136.6% | +19.2% | +131.6% | +17.3% | -46.3% | +46.6% | -492.2% | -9.5% | +21.7% | -13.3% | +5415.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.3% | 9.9% | 14.9% | 10.1% | 6.9% | 9.5% | 6.8% | 9.1% | -20.7% | 6.4% | 10.1% | 5.0% | 4.8% |
| — | +4.5% | +117.1% | +12.0% | +133.1% | +49.2% | -31.9% | +82.1% | -532.8% | -18.1% | +16.1% | -12.8% | +5070.0% | |
| ROA | 0.8% | 3.7% | 5.3% | 3.5% | 2.3% | 3.1% | 2.3% | 2.9% | -7.0% | 2.3% | 3.5% | 1.7% | 1.6% |
| — | +18.2% | +130.5% | +19.0% | +132.4% | +36.8% | -33.7% | +74.6% | -536.0% | -12.0% | +22.6% | -7.4% | +5470.3% | |
| ROIC | 3.2% | 7.2% | 6.4% | 4.9% | 4.6% | 5.0% | 1.8% | 5.2% | -8.1% | 2.9% | 4.8% | 3.1% | 3.1% |
| — | +43.4% | +259.9% | -4.9% | +157.2% | +74.3% | -63.1% | +69.5% | -359.9% | -29.9% | -6.3% | -16.3% | +786.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 5.4% YoY to 1.68x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.39 | — | 1.16 | 1.27 | 1.31 | 1.42 | 1.26 | 1.28 | 1.44 | 1.13 | 1.12 | 1.20 | 1.21 |
| — | — | -8.1% | -0.8% | -9.4% | +25.9% | +12.6% | +7.2% | +19.7% | -5.2% | -6.2% | -7.7% | -8.4% | |
| Debt / EBITDA | 6.03 | — | 6.22 | 7.88 | 8.51 | 8.69 | 14.73 | 7.00 | — | 11.16 | 7.55 | 10.76 | 10.76 |
| — | — | -57.8% | +12.7% | — | -22.1% | +95.0% | -35.0% | — | +23.6% | +0.7% | +4.8% | -70.3% | |
| Current Ratio | 1.60 | 1.68 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 | 1.43 | 1.34 | 1.02 | 1.28 |
| — | +5.4% | +15.3% | +15.1% | +26.9% | +12.0% | -5.8% | +11.7% | -15.6% | +11.0% | +2.9% | -28.4% | -13.4% | |
| Quick Ratio | 1.45 | 1.31 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 | 1.27 | 1.20 | 0.91 | 1.13 |
| — | -9.7% | +18.8% | +20.7% | +31.0% | +14.8% | -8.1% | +5.3% | -17.0% | +10.1% | +3.3% | -28.5% | -13.4% | |
| Interest Coverage | 1.70 | 11.62 | 13.00 | 9.74 | 8.60 | 9.85 | 3.73 | 11.16 | -17.02 | 6.40 | 11.31 | 7.24 | 7.41 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonGilead Sciences, Inc.'s current P/E is 392.0x. The average P/E over the last 4 quarters is 18.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Gilead Sciences, Inc.'s current operating margin is 5.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Gilead Sciences, Inc.'s business trajectory between earnings reports.